Stähli Barbara E, Gebhard Cathérine, Saleh Lanja, Falk Volkmar, Landmesser Ulf, Nietlispach Fabian, Maisano Francesco, Lüscher Thomas F, Maier Willibald, Binder Ronald K
Department of Cardiology, University Heart Center, Zurich, Switzerlan.
Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland.
Catheter Cardiovasc Interv. 2015 Jun;85(7):1240-7. doi: 10.1002/ccd.25788. Epub 2015 Jan 19.
We studied the prognostic value of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP)-ratio, which is independent of individual cutoff levels, in predicting mortality in patients undergoing transcatheter aortic valve replacement (TAVR).
Elevated levels of natriuretic peptides are associated with adverse outcomes across a wide spectrum of cardiovascular diseases. However, cutoff values differ according to age, gender, and body weight.
244 TAVR patients with preprocedural NT-proBNP levels were analyzed, and the predictive value of NT-proBNP-ratio (measured NT-proBNP/maximal normal NT-proBNP values specific for age and gender) on all-cause-mortality was assessed in a multivariate model.
Median NT-proBNP-ratio was 4.2 [IQR 1.8-9.7]. All-cause mortality at 30 days was 3.4% in patients with less than median NT-proBNP-ratio, and 14.0% in patients with more than median NT-proBNP-ratio (P=0.02). All-cause mortality at 1 year was 8.5% in patients with less than median NT-proBNP-ratio, and 32.1% in those with more than median NT-proBNP-ratio (P=0.001). Cumulative survival declined with increasing quartiles of NT-proBNP-ratio (log rank P=0.001). All patients with a NT-proBNP-ratio below 1.5 survived at 1-year follow-up. In ROC analysis, NT-proBNP-ratio significantly predicted 30-day (AUC=0.72; P=0.002) and 1-year all-cause mortality (AUC=0.72; P<0.001). By multivariate Cox regression analysis, NT-proBNP-ratio, chronic obstructive pulmonary disease, and serum creatinine were the only independent predictors of all-cause mortality.
Elevated NT-proBNP-ratio was associated with increased short- and long-term mortality after TAVR, and independently predicted all-cause mortality. NT-proBNP-ratio should be considered in the risk stratification of patients undergoing TAVR.
我们研究了血浆N末端前脑钠肽(NT-proBNP)比值(独立于个体临界值水平)在预测经导管主动脉瓣置换术(TAVR)患者死亡率方面的预后价值。
利钠肽水平升高与广泛的心血管疾病不良结局相关。然而,临界值因年龄、性别和体重而异。
分析了244例术前有NT-proBNP水平的TAVR患者,并在多变量模型中评估NT-proBNP比值(测量的NT-proBNP/特定年龄和性别的最大正常NT-proBNP值)对全因死亡率的预测价值。
NT-proBNP比值中位数为4.2[四分位间距1.8 - 9.7]。NT-proBNP比值低于中位数的患者30天全因死亡率为3.4%,高于中位数的患者为14.0%(P = 0.02)。NT-proBNP比值低于中位数的患者1年全因死亡率为8.5%,高于中位数的患者为32.1%(P = 0.001)。NT-proBNP比值四分位数增加时,累积生存率下降(对数秩检验P = 0.001)。所有NT-proBNP比值低于1.5的患者在1年随访时均存活。在ROC分析中,NT-proBNP比值显著预测30天(AUC = 0.72;P = 0.002)和1年全因死亡率(AUC = 0.72;P < 0.001)。通过多变量Cox回归分析,NT-proBNP比值、慢性阻塞性肺疾病和血清肌酐是全因死亡率的唯一独立预测因素。
NT-proBNP比值升高与TAVR术后短期和长期死亡率增加相关,并独立预测全因死亡率。在TAVR患者的风险分层中应考虑NT-proBNP比值。